about
The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancerPathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationGenomic profiling of B-progenitor acute lymphoblastic leukemiaAdvances in the management of myelofibrosisThe secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control12q24 locus association with type 1 diabetes: SH2B3 or ATXN2?LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitorsStem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.LNK (SH2B3): paradoxical effects in ovarian cancer.ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice.Targeting the interleukin-6/Jak/stat pathway in human malignanciesThe Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cellsA novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia.JAK Kinases in Health and Disease: An UpdateTargeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaIncreased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosisNormal and malignant megakaryopoiesis.Genetic loss of SH2B3 in acute lymphoblastic leukemia.Genomic characterization of childhood acute lymphoblastic leukemia.Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.Mouse models of diseases of megakaryocyte and platelet homeostasis.JAK2 inhibitors: are they the solution?The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis.Myeloproliferative neoplasm animal modelsRole of the adaptor protein LNK in normal and malignant hematopoiesis.Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Bridges between Cell Cycle Regulation and Self-Renewal MaintenanceMolecular classification of myeloproliferative neoplasms-pros and cons.Molecular genetics of myelofibrosis and its associated disease phenotypes.LNK mutations and myeloproliferative disorders.The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis.Lnk deficiency partially mitigates hematopoietic stem cell aging.Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.
P2860
Q26770682-32146989-18B8-4044-B4FB-4299CF4809D5Q26779960-C184B23E-07A7-4FB2-AD72-BE429D5B7763Q26829976-877CC53C-1458-4CF7-B0B0-00D3C45127B3Q27008072-888D0EFF-17BA-455C-93D3-F7A917D2A0DEQ28082685-251207E6-8181-4434-86BA-CAE902B0D5DCQ28242134-C97AFD78-8385-4941-BDC2-738D7E18412AQ28274115-A8DB09A9-FDF5-4F95-B685-5B72EC7D8C92Q31156217-10139BE2-3CB1-4E7B-9483-BE76263B7B86Q34302585-28704AD3-9EAB-4713-85FF-7F045857B8A2Q34479990-F00603D8-5699-45C5-BCED-0D4B58E91DF6Q35925127-B72935FA-1226-44BB-8750-DBA65E4A47CAQ35998214-5A667249-13C8-4349-A239-4C3A2C3D8CCDQ36005362-41559DD0-68D6-4B3E-9B69-4168B04F084DQ36072642-F47C2378-0AC4-48F9-B49A-6EC33E0A931EQ36285745-12F595B7-8D1F-4893-9C45-F621B35C476FQ36352535-8F0FE753-9C8A-4AE4-A13B-8F3419F8764DQ36842989-AE7F05D3-C8B8-4777-BEBB-D184DD5B9A7AQ36901651-8C0DE36B-A105-4539-85CE-68AA138A9E9CQ36907588-4ECDD897-3D6B-4195-809F-1B362DF9FDEBQ36909019-3CE7021C-B088-4769-9490-F38F5BB30407Q37215146-B401825F-ADB4-4629-8955-C2022E23BB62Q37359118-4DB8ECF4-3BD8-47FE-B7A8-A40732480B6FQ37409325-0E836CE2-7B30-47A9-A6EE-2632102FC422Q37833893-02EB90BA-0C66-4C85-9AB5-1FA9D1AFF2A6Q37888528-03871E69-FBD7-4940-9789-44EAEFD1FA76Q37950581-44DCE912-0329-442E-8105-87EB0EE7D8DDQ38044625-E91BBF08-4AC8-4B94-A207-46D96CFC3E26Q38046320-1993A6DF-609C-4762-B093-8563D5B3723FQ38050407-1F87DFF6-EE36-4A41-8CB6-7520586263A3Q38081267-BEACBA54-6355-4AE5-BC1E-306618FFB21BQ38103252-AD703C84-60B8-4EE5-A795-B7DBCE1585F6Q38148982-5EE2FBF2-90FB-46A7-8FA5-9C36C6444A0FQ38208010-9FB96D95-908A-4A6D-97BA-085D12DC685BQ38667486-A0A55BF3-C5FD-45AE-A471-561A743D1928Q39292396-AC6FD31F-E7F0-43D8-BBD1-6DD73F84C94FQ39788785-724210CA-8F3B-4035-BD9B-AC396217A8DBQ40298579-4BD02DCD-18ED-4DBB-9542-B470666E7E04Q40645397-C25D15F4-DC2A-4E26-AF39-4021EE3D051BQ41381598-0A5D6651-F7C4-4141-B42C-0719CE3A2A6DQ42583762-4CC05ED3-7483-4A0F-8258-BDE6E9D093E7
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Lnk constrains myeloproliferative diseases in mice.
@ast
Lnk constrains myeloproliferative diseases in mice.
@en
type
label
Lnk constrains myeloproliferative diseases in mice.
@ast
Lnk constrains myeloproliferative diseases in mice.
@en
prefLabel
Lnk constrains myeloproliferative diseases in mice.
@ast
Lnk constrains myeloproliferative diseases in mice.
@en
P2093
P2860
P356
P1476
Lnk constrains myeloproliferative diseases in mice.
@en
P2093
Alexey Bersenev
Gerd A Blobel
Jiang Jing
Joanna Balcerek
Kudakwashe R Chikwava
P2860
P304
P356
10.1172/JCI42032
P407
P577
2010-05-10T00:00:00Z